In the largest meeting of its kind, nearly 4,000 doctors, scientists and clinicians from diverse disciplines will meet in Orlando, Fla., Oct. 11 – 13, 2012, to present the latest advancements in cystic fibrosis research, care and drug development.
Highlighted topics of the 26th annual North American Cystic Fibrosis Conference include:
- Accelerating discovery of potential new therapies that target the basic genetic defect in CF.
- Updates on the diagnosis and management of pulmonary disease.
- Overcoming barriers to CF medication adherence.
- Partnering with patients and families to improve CF care.
Sponsored by the Cystic Fibrosis Foundation, the meeting takes place at a time of tremendous advances in CF research and care. In January, the U.S. Food and Drug Administration approved Kalydeco™, the first drug to treat the underlying cause of CF in a small group of people with the disease. This milestone opens the door to research that may eventually lead to similar treatments for all who have CF.
Cystic fibrosis is a fatal genetic disease that causes life-threatening lung infections and premature death. Fifty years ago, most children with CF died before reaching Kindergarten. Today, due to Cystic Fibrosis Foundation-supported drug research and care, people with CF are living into their 30s, 40s and beyond.
WHAT:
The 26th Annual North American Cystic Fibrosis Conference, the largest international gathering of cystic fibrosis research scientists and clinicians.
WHEN & WHERE:
Thursday, Oct. 11 – Saturday, Oct. 13, 2012, at the Orange County Convention Center.
